Tirzepatide cost and pricing: what it really costs in 2025

Last updated 2026-07-27

How much does tirzepatide actually cost per month?

The honest answer is: it depends which tirzepatide you're talking about, and whether insurance is in the picture. There isn't one price. Eli Lilly's list price (the "wholesale acquisition cost" before any rebates or discounts) for Zepbound is $1,059.87 for a one-month supply of the single-dose vials, according to Lilly's own pricing statements accompanying FDA approval ^[1]. Mounjaro, the type 2 diabetes version of the same drug, lists around $1,086.37 monthly depending on formulation ^[2]. These are list prices. Almost nobody with commercial insurance pays that number, and even self-pay patients using Lilly's direct channels usually pay far less. Compounded tirzepatide, made by licensed compounding pharmacies rather than Lilly, has historically run $200 to $500 a month depending on dose and provider markup. That gap exists because compounders aren't paying for the clinical trials, marketing, and patent protection baked into the branded price. But compounded product is legally distinct from FDA-approved Zepbound or Mounjaro, and its legal availability narrowed sharply after the FDA removed tirzepatide from the drug shortage list in late 2024, which restricts when pharmacies can legally compound a copy of an approved drug ^[3]. So the real number for you is somewhere between "basically free after insurance and a savings card" and "over a thousand dollars a month, self-pay, at full list price." The sections below break down where you'll likely land.

What does Zepbound cost without insurance?

Self-pay, no insurance, no savings card: Zepbound's list price is $1,059.87 per month for the single-dose vial option ^[1]. That's before any pharmacy dispensing fee. Lilly has pushed hard to lower this for cash-pay patients through its own direct-to-consumer channel, LillyDirect, and through vial-based (rather than pen-based) dosing. As of 2024-2025, Lilly offered lower cash prices for certain vial doses through LillyDirect, in some cases in the $349 to $499 range for starter doses, though pricing tiers have shifted as Lilly has adjusted its self-pay program multiple times since launch. Because these self-pay programs change frequently and aren't set by statute, treat any specific number older than a few months as provisional and check Lilly's current self-pay page before budgeting. Mounjaro's list price runs similarly, around $1,086 per month for the standard pen kit ^[2]. Neither of these list prices reflects manufacturer rebates paid to insurers or pharmacy benefit managers, which is why the "real" transaction price is usually much lower than the sticker figure, even for people who technically have no insurance discount applied.

How much is tirzepatide with insurance?

With commercial insurance that covers Zepbound or Mounjaro, your out-of-pocket cost typically lands somewhere between $25 and $650 a month, depending on your specific plan's formulary tier and whether you qualify for a manufacturer copay card. Lilly's Zepbound Savings Card has offered eligible commercially-insured patients pricing as low as $25 for a 1 or 3-month prescription, capped at a maximum savings amount per year, though exact caps and eligibility rules (commercial insurance required, not valid with Medicare or Medicaid) change periodically and are set by Lilly, not by law. Check the terms on your specific card before assuming it applies. Medicare is a separate story. Medicare Part D has historically not covered GLP-1 drugs for weight loss alone, only for FDA-approved indications like type 2 diabetes or, more recently, reducing cardiovascular risk in patients with obesity and known heart disease, an indication FDA granted Zepbound-class drugs based on outcome trial data. Medicaid coverage for tirzepatide varies enormously by state; some states cover it for diabetes and exclude weight-loss-only prescriptions entirely. If your employer-sponsored plan does cover it for weight loss, expect a specialty-tier copay, often $50 to $150 a month, though some plans still apply full coinsurance (a percentage of the drug's cost) rather than a flat copay, which can push your share well above $300.

How much does compounded tirzepatide cost compared to brand name?

Compounded tirzepatide has typically been priced far below branded Zepbound or Mounjaro, often in the $150 to $500 monthly range depending on dose, pharmacy, and whether it's dispensed as a single vial or a multi-dose kit with supplies included. The price gap is real and it's not mysterious: compounding pharmacies aren't recovering the cost of the clinical trials that got tirzepatide approved (Lilly's SURMOUNT and SURPASS programs involved tens of thousands of trial participants across multiple studies), and they don't carry the same patent-protected pricing power. But cheaper isn't automatically equivalent. Compounded tirzepatide is not FDA-approved, meaning it hasn't been reviewed by FDA for safety, effectiveness, or manufacturing consistency the way Zepbound and Mounjaro have. The FDA's compounding rules matter a lot here. Under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, pharmacies can generally only compound a copy of a commercially available approved drug when that drug is in shortage, or for a patient with a documented clinical need the approved product doesn't meet (like an allergy to an inactive ingredient) ^[4]. FDA removed tirzepatide injection from its drug shortage list in December 2024 ^[3], which narrowed the legal basis for mass-compounding a direct copy nationwide. Reputable compounding pharmacies responded by tightening who they'll dispense to and under what clinical rationale; less reputable ones kept selling regardless. That distinction is worth caring about, because it correlates with sourcing quality, more than legal exposure. If you're going the compounded route, the person who matters most is the prescriber and pharmacy doing quality oversight, not the price tag. A $180/month vial from an unaccountable source is not a bargain if the concentration is wrong or the vial isn't sterile.

Zepbound vs Mounjaro: does the price differ, and why?

Zepbound and Mounjaro both contain tirzepatide at the same available doses. The difference is the FDA-approved indication on the label: Mounjaro is approved for type 2 diabetes based on the SURPASS trial program, and Zepbound is approved for chronic weight management based on the SURMOUNT trial program ^{[5] [6]}. List prices are close but not identical: Zepbound at $1,059.87/month versus Mounjaro around $1,086.37/month for comparable dosing, per Lilly's published pricing at launch ^{[1] [2]}. The bigger difference isn't the list price, it's insurance behavior. Because Mounjaro is FDA-approved specifically for diabetes, insurers (including many Medicare Part D plans) are far more likely to cover it when a patient has a T2D diagnosis. Zepbound's weight-loss-only indication runs into far more formulary exclusions, especially with Medicare, which historically hasn't covered anti-obesity medications under Part D. Some patients have been prescribed Mounjaro off-label for weight loss specifically because their insurance covers diabetes drugs but excludes obesity drugs. That's a real, common workaround, but it depends entirely on your plan's rules and your prescriber's judgment, and insurers have gotten more aggressive about auditing diagnosis codes tied to GLP-1 prescriptions.

Why is tirzepatide so expensive in the first place?

Three things drive the price: development cost recovery, patent exclusivity, and the specialty-drug supply chain. Lilly ran a large, multi-year trial program to get tirzepatide approved twice, once for diabetes (SURPASS-1 through SURPASS-5, NCT03954834 among others) and once for obesity (SURMOUNT-1, NCT04184622, and subsequent SURMOUNT trials) ^{[5] [6]}. Trials at that scale, thousands of participants followed for 40-plus weeks or longer, cost hundreds of millions of dollars, and current U.S. drug law gives the manufacturer patent-protected exclusivity to recover that cost before generic or biosimilar competition is allowed. Tirzepatide is also a peptide, not a small-molecule pill. Manufacturing GLP-1/GIP peptides at scale is genuinely harder and more expensive than making a generic tablet, which is part of why even compounded versions aren't dirt cheap the way, say, generic metformin is. Finally, the U.S. drug pricing system routes list prices through pharmacy benefit managers and rebate negotiations that most patients never see. The number on Lilly's press release isn't what insurers actually pay after rebates; it's closer to a starting point for negotiation. That opacity is exactly why your out-of-pocket cost can swing from $25 to over $1,000 for the identical vial.

What's included in the price, and what costs extra?

A month's supply typically covers the drug itself, whether that's a pre-filled pen (branded) or a vial requiring reconstitution and a syringe (common with compounded product and some branded self-pay vial options). What's often not included: syringes and needles if you're using a vial-based product, alcohol swabs, a sharps disposal container, and follow-up provider visits to adjust your dose. If you're new to vial dosing, it's worth reading through how to reconstitute Tirz Rx and Tirz Rx how to inject before you assume the sticker price is your total monthly cost. Supplies typically add somewhere in the $10 to $30 monthly range if you're buying insulin syringes and swabs separately, though many compounding pharmacies now bundle these in. Provider visit costs vary widely depending on whether you're seeing a primary care doctor, an endocrinologist, or a telehealth weight-management service, and whether that visit is billed to insurance or paid directly. Lab work (kidney function, sometimes lipase or amylase if there's any pancreatitis concern) is another line item that can be billed separately depending on your provider's protocol.

How does the starting dose affect cost?

Tirzepatide is dosed in a slow titration: most protocols start at 2.5 mg weekly for four weeks, then step up in 2.5 mg increments toward a maintenance dose, commonly landing somewhere between 5 mg and 15 mg weekly depending on tolerance and response ^[5]. Branded Zepbound and Mounjaro are priced per box/kit regardless of which of the six approved doses (2.5, 5, 7.5, 10, 12.5, 15 mg) you're on; the monthly list price doesn't change much across the dose range because you're still getting one month's worth of pens. Compounded pricing, on the other hand, is often priced per milligram or per vial concentration, so your monthly cost can actually rise as you titrate upward, since higher doses mean drawing more volume from a vial or needing a higher-concentration vial altogether. If you're mapping out your titration schedule and want to know exactly what dose you'll be on by month three or four, the Tirz Rx dosage guide and Tirz Rx dosage calculator are useful for planning both the clinical schedule and the rough cost trajectory, since dose changes are the main lever affecting your monthly compounded price.

How long do you have to take it, and what does that mean for total cost?

This is the number most people underestimate. Tirzepatide isn't a short course, it's a chronic medication, and the trial data backs that up directly. In SURMOUNT-4 (NCT04660643), participants who stopped tirzepatide after a 36-week lead-in regained a substantial share of the weight they'd lost within the following 52 weeks off the drug, while those who stayed on treatment kept losing or maintained their loss . That's the core evidence behind why most prescribers treat this as an ongoing medication rather than a fixed course, similar to how you'd treat blood pressure medication. That changes the cost conversation. A $1,000/month drug for 3 months is $3,000. The same drug for 2 years, which is closer to realistic long-term use for many patients, is $24,000 before any insurance or savings card. If you're weighing whether to try a shorter run first, it's worth reading Tirz Rx cycle length to understand what the evidence actually says about stopping versus continuing, rather than assuming a few months will "finish the job."

Are there hidden costs beyond the monthly price?

Yes, and they're worth budgeting for honestly rather than discovering later. Side effect management is the biggest one. GI side effects (nausea, vomiting, diarrhea, constipation) are common, reported in roughly 20 to 30 percent or more of trial participants depending on the study and dose, per the SURMOUNT-1 and SURPASS trial safety data ^{[5] [6]}. Most are mild-to-moderate and improve over the titration period, but some patients need anti-nausea medication, which is its own cost and prescription. Gallbladder-related events (cholelithiasis, cholecystitis) showed up at a higher rate in tirzepatide arms than placebo across the SURMOUNT program, and pancreatitis, while uncommon, is a recognized signal with GLP-1/GIP drugs that prescribers monitor for ^[6]. Neither is something you budget for directly, but both are reasons an ER visit or gallbladder ultrasound could enter your total cost picture unexpectedly. Tirzepatide also carries a boxed warning about thyroid C-cell tumors, based on rodent studies, and it's contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) . This isn't a cost issue directly, but if you have that history, tirzepatide isn't an option regardless of price, and that's worth knowing before you spend time comparing pharmacy quotes. Injection site reactions are also common enough that where you inject matters for comfort; see Tirz Rx injection sites if you're getting bruising or irritation that's making you consider switching supply sources.

Is compounded tirzepatide worth the lower price?

It depends heavily on the pharmacy, and this is the honest, unsatisfying answer. A licensed 503A or 503B compounding pharmacy operating under a legitimate clinical rationale, with real sourcing documentation and third-party testing, is a genuinely different product than an unregulated online seller shipping something labeled "tirzepatide" with no chain of custody. FDA has published warnings about compounded semaglutide and tirzepatide products containing incorrect concentrations or being sourced from unregistered facilities, and some seized products have tested as containing no active ingredient at all or the wrong salt form ^{[3] [4]}. The price difference between a well-run compounding pharmacy and branded Zepbound isn't free money, it reflects real avoided costs (no trial expense, no patent premium) but it also means you're relying entirely on that specific pharmacy's quality practices rather than FDA's premarket review. That's a legitimate tradeoff some patients choose deliberately, especially when insurance won't cover branded product at all. It's not a tradeoff to make based on price alone without checking the pharmacy's licensing and sourcing. If you're evaluating a provider-reviewed compounded option, look for one where a licensed clinician actually reviews your history before prescribing, rather than a checkout page that ships based on a form. Tirz Rx works through that provider-reviewed model, connecting patients to prescribers who evaluate eligibility before any prescription is written, with product ultimately dispensed through a licensed pharmacy partner, not sold directly by Tirz Rx itself.

How can you actually lower your cost?

A few levers are real and worth trying in order. First, ask your prescriber about Mounjaro versus Zepbound if you have type 2 diabetes; insurance coverage odds are meaningfully better for the diabetes indication. Second, check Lilly's current savings card and LillyDirect self-pay vial pricing before assuming you're stuck at list price; these programs change often and current terms are only accurate on Lilly's own pages. Third, if your employer plan excludes weight-loss drugs entirely, ask HR during open enrollment whether a plan tier with GLP-1 coverage exists; more employers have added it as of 2024-2025 given demand. Fourth, if you're going compounded, get pricing from more than one licensed pharmacy since markup varies, but never let price alone override licensing and sourcing checks. Finally, budget for the long haul rather than a 3-month trial; per-month savings-card discounts often have annual caps, so your true annual cost matters more than the headline monthly number.

Frequently asked questions

How much does Zepbound cost per month without insurance?

Zepbound's list price is $1,059.87 for a one-month supply, per Eli Lilly's published pricing ^[1]. Actual self-pay cost is often lower through Lilly's direct-to-consumer vial program, which has offered discounted cash pricing tiers, though these change periodically so check Lilly's current self-pay terms before budgeting.

How much does Mounjaro cost with insurance?

With commercial insurance covering Mounjaro for type 2 diabetes, copays commonly range from $25 (with Lilly's savings card, subject to eligibility and annual caps) to $100-plus depending on your plan's specialty tier. Without qualifying coverage, list price runs around $1,086.37 per month ^[2].

Does Medicare cover tirzepatide?

Medicare Part D has generally not covered GLP-1 drugs prescribed solely for weight loss. Coverage is more likely when tirzepatide is prescribed for an FDA-approved indication like type 2 diabetes, or the newer cardiovascular risk reduction indication in patients with obesity and existing heart disease. Coverage rules vary by plan and change yearly, so check your specific Part D formulary.

Why is compounded tirzepatide so much cheaper than Zepbound?

Compounding pharmacies don't bear the cost of the clinical trials or patent exclusivity built into Zepbound's price, so they can charge less, often $150 to $500 monthly. But compounded product isn't FDA-approved, and legal availability narrowed after FDA removed tirzepatide from its drug shortage list in December 2024 ^[3], which restricts when pharmacies can legally compound it.

Is compounded tirzepatide legal?

It can be, under specific conditions. Federal law (FD&C Act sections 503A and 503B) allows compounding a copy of an approved drug mainly during a declared shortage or for documented individual patient need ^[4]. Since tirzepatide left FDA's shortage list in December 2024, blanket compounding of a direct copy has a narrower legal basis, though compounding for legitimate individualized need continues at licensed pharmacies.

How much do syringes and supplies add to the monthly cost?

If you're on a vial-based product (common with compounded tirzepatide or some self-pay branded options), expect to add roughly $10 to $30 a month for insulin syringes, alcohol swabs, and a sharps container, unless your pharmacy bundles these into the price. Pre-filled branded pens don't require separate syringes.

Does the price change as my dose increases?

For branded Zepbound and Mounjaro, list price stays roughly flat across the six approved doses since you're buying one month's kit regardless of dose. For compounded tirzepatide priced per milligram or vial concentration, cost often rises as you titrate to higher maintenance doses, since you need more drug volume per week.

How long will I need to take tirzepatide, and what does that mean for total cost?

Trial data from SURMOUNT-4 (NCT04660643) shows patients who stopped tirzepatide after 36 weeks regained significant weight over the next year, while those who continued kept losing or maintained their results ^[8]. Most prescribers treat it as long-term therapy, so budget for years, not months, when estimating total cost.

Can I get tirzepatide covered if I don't have diabetes?

Some plans cover Zepbound for weight management if you meet BMI-based criteria (generally 30+, or 27+ with a weight-related condition), matching the SURMOUNT-1 trial's enrollment criteria ^[6]. Coverage varies enormously by employer and plan; many exclude anti-obesity medications entirely regardless of BMI.

What's the difference between Zepbound and Mounjaro pricing?

Both contain tirzepatide at the same available doses. List prices are close: Zepbound around $1,059.87/month, Mounjaro around $1,086.37/month ^[1][2]. The real difference is insurance coverage likelihood, since Mounjaro's diabetes indication gets approved by insurers, including some Medicare plans, far more often than Zepbound's weight-loss-only indication.

Are there serious side effects that could add unexpected costs?

Yes. Gallbladder problems (cholelithiasis, cholecystitis) occurred at higher rates in tirzepatide trial arms than placebo, and pancreatitis is a recognized though uncommon signal with GLP-1/GIP drugs ^[6]. Tirzepatide also carries a boxed warning for thyroid C-cell tumor risk and is contraindicated with a personal or family history of MTC or MEN 2 ^[9]. These aren't routine budget items but can mean unplanned medical costs.

Does insurance cover tirzepatide for prediabetes or just diabetes and obesity?

Coverage for prediabetes alone is inconsistent and generally weaker than for confirmed type 2 diabetes or FDA-approved weight-management criteria. Tirzepatide (Mounjaro) is FDA-approved for type 2 diabetes based on the SURPASS trials ^[5]; Zepbound is approved for chronic weight management per SURMOUNT-1 criteria ^[6]. Prediabetes-only prescriptions often fall outside standard formulary coverage.

Sources

1. Eli Lilly, Mounjaro pricing information: Mounjaro list price around $1,086.37 per month
2. FDA, Drug Shortages Database - Tirzepatide Injection: FDA removed tirzepatide injection from the drug shortage list in late 2024
3. NCT03954834, SURPASS clinical trial program (ClinicalTrials.gov): SURPASS trial program supporting Mounjaro's type 2 diabetes approval
4. NCT04184622, SURMOUNT-1 trial (ClinicalTrials.gov): SURMOUNT-1 trial supporting Zepbound's weight management approval, including safety and GI/gallbladder event data
5. FDA, Zepbound Prescribing Information: Approved tirzepatide dosing titration schedule from 2.5 mg to 15 mg weekly
6. NCT04660643, SURMOUNT-4 trial (ClinicalTrials.gov): Weight regain after tirzepatide discontinuation versus continued treatment